Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer

Xueliang Wang,Yi Fang,Wei Liang,Chi Chun Wong,Huanlong Qin,Yaohui Gao,Meinong Liang,Lei Song,Yongxin Zhang,Miao Fan,Chuanfa Liu,Harry Cheuk-Hay Lau,Lixia Xu,Xiaoxing Li,Wu Song,Junlin Wang,Na Wang,Tao Yang,Mengmiao Mo,Xiang Zhang,Jingyuan Fang,Bing Liao,Joseph J.Y. Sung,Jun Yu
DOI: https://doi.org/10.1016/j.ccell.2024.08.019
IF: 50.3
2024-10-15
Cancer Cell
Abstract:Wang et al. report that colorectal cancer (CRC)-promoting gut pathogen Fusobacterium nucleatum paradoxically sensitizes microsatellite stable colorectal cancer (MSS CRC) to anti-PD-1 in experimental models and predicts favorable response to anti-PD-1 in patients with MSS CRC. Mechanistically, F. nucleatum-derived butyric acid relieves CD8+ TIL exhaustion by repressing PD-1 via a HDAC3/8-TBX21 axis.
oncology,cell biology
What problem does this paper attempt to address?